Bluejay Therapeutics Overview
- Year Founded
-
2019
- Status
-
Acquired/Merged
- Employees
-
33
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$450M
Bluejay Therapeutics General Information
Description
Developer of therapeutic medicines designed to provide curative treatments for serious viral and liver diseases. The company offers monoclonal antibody therapies for chronic hepatitis infections and a liver-targeting platform for liver disease treatment, enabling patients with viral and liver diseases to access targeted therapies and curative treatment approaches.
Contact Information
Website
www.bluejaytx.comCorporate Office
- 255 Shoreline Drive
- Suite 450
- Redwood City, CA 94065
- United States
Corporate Office
- 255 Shoreline Drive
- Suite 450
- Redwood City, CA 94065
- United States
Bluejay Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 23-Jan-2026 | $450M | Completed | Clinical Trials - Phase 2 | ||
| 3. Later Stage VC (Series C) | 09-May-2024 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC (Series B) | 16-Aug-2022 | $41M | $61M | Completed | Pre-Clinical Trials | |
| 1. Early Stage VC (Series A) | 17-Jun-2021 | $20M | $20M | Completed | Pre-Clinical Trials |
Bluejay Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C-1 | ||||||||
| Series C | ||||||||
| Series B | ||||||||
| Series A-1 | 1,146,656 | $0.000010 | $0.3 | $3.7 | $3.7 | 1x | $3.7 | 1.97% |
| Series A | 5,408,768 | $0.000010 | $0.3 | $3.7 | $3.7 | 1x | $3.7 | 9.29% |
Bluejay Therapeutics Comparisons
Industry
Financing
Details
Bluejay Therapeutics Competitors (39)
One of Bluejay Therapeutics’s 39 competitors is Imcare Biotech, a Venture Capital-Backed company based in Doylestown, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Imcare Biotech | Venture Capital-Backed | Doylestown, PA | ||||
| NorthSea Therapeutics | Venture Capital-Backed | Amsterdam, Netherlands | ||||
| Altimmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Apeptico | Formerly VC-backed | Vienna, Austria | ||||
| Galectin Therapeutics | Corporation | Norcross, GA |
Bluejay Therapeutics Patents
Bluejay Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026136783-A1 | Fatty acid synthase inhibitors and methods of use thereof | Pending | 19-Dec-2024 | ||
| JP-2026522135-A | Fusion proteins containing il-21 variants for the treatment of cancer and viral diseases | Pending | 03-Jul-2023 | ||
| AU-2024289820-A1 | Fusion proteins containing il21 muteins for treating cancer and viral diseases | Pending | 03-Jul-2023 | ||
| AU-2024289820-A9 | Fusion proteins containing il21 muteins for treating cancer and viral diseases | Pending | 03-Jul-2023 | ||
| EP-4739344-A2 | Fusion proteins containing il21 muteins for treating cancer and viral diseases | Inactive | 03-Jul-2023 | A61K47/6813 |
Bluejay Therapeutics Signals
Bluejay Therapeutics Former Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Arkin Capital | Asset Manager | Minority | ||
| Frazier Healthcare Partners | PE/Buyout | Minority | ||
| HBM Healthcare Investments | Venture Capital | Minority | ||
| InnoPinnacle | Growth/Expansion | Minority | ||
| Novo Holdings | Venture Capital | Minority |
Bluejay Therapeutics FAQs
-
When was Bluejay Therapeutics founded?
Bluejay Therapeutics was founded in 2019.
-
Where is Bluejay Therapeutics headquartered?
Bluejay Therapeutics is headquartered in Redwood City, CA.
-
What is the size of Bluejay Therapeutics?
Bluejay Therapeutics has 33 total employees.
-
What industry is Bluejay Therapeutics in?
Bluejay Therapeutics’s primary industry is Drug Discovery.
-
Is Bluejay Therapeutics a private or public company?
Bluejay Therapeutics is a Private company.
-
What is the current valuation of Bluejay Therapeutics?
The current valuation of Bluejay Therapeutics is .
-
What is Bluejay Therapeutics’s current revenue?
The current revenue for Bluejay Therapeutics is .
-
How much funding has Bluejay Therapeutics raised over time?
Bluejay Therapeutics has raised $243M.
-
Who are Bluejay Therapeutics’s investors?
Arkin Capital, Frazier Healthcare Partners, HBM Healthcare Investments, InnoPinnacle, and Novo Holdings are 5 of 13 investors who have invested in Bluejay Therapeutics.
-
Who are Bluejay Therapeutics’s competitors?
Imcare Biotech, NorthSea Therapeutics, Altimmune, Apeptico, and Galectin Therapeutics are some of the 39 competitors of Bluejay Therapeutics.
-
When was Bluejay Therapeutics acquired?
Bluejay Therapeutics was acquired on 23-Jan-2026.
-
Who acquired Bluejay Therapeutics?
Bluejay Therapeutics was acquired by Mirum Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process